UPPSALA, Sweden, July 21, 2005 (PRIMEZONE) -- Q-Med:
- Turnover during the period amounted to SEK 437.5 (401.1) million, an increase of 9 percent.
- Operating income amounted to SEK 21.4 (164.1) million. Adjusted for revenues and expenses of a one-time nature operating income amounted to SEK 31.7 (33.4) million.
- Net income after tax amounted to SEK 23.6 (166.8) million.
- Earnings per share for the period were SEK 0.95 (6.72).
- Oxalate project obtains external financing.
- Continued strong growth, 54 percent, for the Hospital Healthcare product area.
Q-Med is a rapidly growing and profitable biotechnology/medical device company that develops, produces, markets and sells medical implants. All products are based on the company's patented NASHA technology - Non-Animal Stabilized Hyaluronic Acid. The products covered by the RESTYLANE trademark are used for the filling out of lips and facial wrinkles and for facial contouring and today account for the majority of sales. RESTYLANE is sold in over 70 countries and has been approved in the USA. DUROLANE, Q-Med's product for the treatment of osteoarthritis of the hip and knee joints, has been approved in Europe since May 2001. DEFLUX is a product
This information was brought to you by Waymaker http://www.waymaker.net
The following files are available for download:
http://wpy.waymaker.net/client/waymaker1/WOLReleaseFile.aspx?id=117378&fn=wkr0001.pdf